コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 vena cava is a rare but important congenital vascular anomaly.
2 involves the focal development of a distinct vascular anomaly.
3 nd guide medical therapy in individuals with vascular anomalies.
4 heranostics has started for the treatment of vascular anomalies.
5 elated to oral sirolimus in populations with vascular anomalies.
6 tissue from individuals with other types of vascular anomalies.
7 ent of the inferior vena cava (IVC) were the vascular anomalies.
8 ur understanding of vascular development and vascular anomalies.
9 effects of recent and previous therapies for vascular anomalies.
10 promote angiogenesis and the development of vascular anomalies.
11 icoagulation when confronted with underlying vascular anomalies.
12 that have minuscule function of irreparable vascular anomalies.
13 rious cartilaginous tissues and skeletal and vascular anomalies.
14 ns and susceptibility genes in patients with vascular anomalies, (3) recognition of new risk stratifi
16 is increasingly being used to treat various vascular anomalies, although evidence of its efficacy is
20 e describe our approach in 5 recipients with vascular anomalies and significant comorbidities, includ
22 radial anomalies, and in DRS with deafness, vascular anomalies, and cognitive deficits, respectively
24 ory of multiple hospitalisations for foci of vascular anomalies appearing progressively in the upper
33 antation because of the greater incidence of vascular anomalies, associated renal anomalies, and pred
34 rved for 2 years (May 2013 to June 2015) for vascular anomalies at a tertiary care referral center.
35 atic patients has suggested a range of other vascular anomalies, but the true prevalence of such lesi
38 ar Anomalies Interest Group, representing 81 vascular anomaly centers (VACs) serving individuals up t
39 ort here that this deletion also resulted in vascular anomalies characterized by extreme variability
40 21 years with HNLM who were evaluated in the vascular anomalies clinic and prospectively enrolled in
41 emangioma," is a non-hereditary, congenital, vascular anomaly comprised of aberrant clusters of malfo
44 ovides information regarding hemodynamics of vascular anomalies, differentiating high- and low-flow v
46 RI) is an effective modality for classifying vascular anomalies due to its ability to delineate the e
47 reported a high prevalence of extracoronary vascular anomalies, especially fibromuscular dysplasia (
48 s needed to understand the etiology of these vascular anomalies, FA should be considered in the evalu
51 approach, focusing on Mendelian disorders of vascular anomalies, has been particularly fruitful for t
52 ntified in affected tissues of patients with vascular anomalies, implicating the Snrk-1-Dusp-5 signal
57 Dominant mutations of either in humans cause vascular anomalies in the brain, known as cerebral caver
59 plication secondary to a rare and unexpected vascular anomaly in a pediatric renal transplant that re
61 was severely affected in the mutant embryos: vascular anomalies included decreased complexity of the
62 atomical mapping, the complete evaluation of vascular anomalies includes hemodynamic characterization
63 Pathological biomechanical signaling induces vascular anomalies including cerebral cavernous malforma
64 ation and vessel maturation are hallmarks of vascular anomalies including venous malformation (VM).
66 members of the Pediatric Hematology-Oncology Vascular Anomalies Interest Group, representing 81 vascu
67 y the International Society for the Study of Vascular Anomalies into 2 major groups: vascular tumors
68 The International Society for the Study of Vascular Anomalies (ISSVA) classification is a comprehen
70 yndromic association characterized by cardio-vascular anomalies, joint hyperlaxity, and various degre
72 RIAL/METHODS: Twenty pediatric patients with vascular anomalies located in the cervicofacial region u
73 may have coexisting iatrogenic or congenital vascular anomalies making transplantation difficult.
75 standing PIK3CA's role in the development of vascular anomalies may inform therapeutic strategies to
76 y based on the type, size, and extent of the vascular anomaly, necessitating accurate diagnosis and c
77 cavernous malformations (CCM) are congenital vascular anomalies of the brain that can cause significa
78 avernous malformations (CCMs) are congenital vascular anomalies of the central nervous system that ca
79 Cerebral cavernous malformations (CCMs) are vascular anomalies of the central nervous system, compri
81 Multiple modalities of treatment exist for vascular anomalies of the head and neck, including medic
91 in NTS antibody-injected follicles indicated vascular anomalies, so the response of monkey ovarian en
92 webbing, increased chest diameter, and these vascular anomalies suggests that in utero, centrally loc
95 erebral cavernous malformations are acquired vascular anomalies that constitute a common cause of cen
96 al cavernous malformations (CCMs) are common vascular anomalies that develop in the central nervous s
98 anding of PIK3CA dysregulation in a range of vascular anomalies that particularly affect low-perfused
99 alformation (AVM) is a fast-flow, congenital vascular anomaly that may arise anywhere in the body.
100 rt wine birthmark, is a cutaneous congenital vascular anomaly that occurs in 0.1%-2% of newborns.
104 the severity of bullous schisis or RD, other vascular anomalies were observed in patients both with a
107 anol level was evaluated in 71 patients with vascular anomalies who underwent ethanol embolization, s
108 ully understand the etiology of these subtle vascular anomalies, widefield FA should be conducted in
109 enotypic severity, we demonstrated that most vascular anomalies with overgrowth harbor postzygotic ga
110 netic variants associated with a spectrum of vascular anomalies with overgrowth, ranging from mild to
113 functional heart and blood flow and exhibit vascular anomalies within major blood vessels as well.